Top Tweets for #Capmatinib
🌟Cancer-Associated Fibroblasts (#CAFs) actively drive resistance to ALK inhibitors in #NSCLCs
💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo.
We offer for research use only.
🔥Hot Off the Press | #CAFs actively drive resistance to ALK inhibitors in #NSCLCs
💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo
🌟We provide alectinib, capmatinib and cilengitide for research use
For MET-alt osi refractory #NSCLC, our #realworld study found #Capmatinib + osi produced a durable response (mPFS ~18m). Big advance for #targeted therapy! Thank you @ClinicalLung @MMarmarelis @CharuAggarwalMD @LovaSunMD
https://t.co/Bv19KWRLmz
New Research in our October issue:
#Capmatinib in MET exon 14-mutated non-small-cell #lungcancer #NSCLC: final results from the open-label, phase 2 GEOMETRY mono-1 trial https://t.co/g1rhfDOScj
7 new drugs/indications were approved by @FDAOncology for lung cancer in 2022:
- #Nivolumab in neoadj
- #Capmatinib
- #TDxD
- #Selpercatinib
- #Adagrasib
- More IO options
Here is a summary table:
#MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #OncEd #MedEd
8 new drugs/indications were approved by @FDAOncology for Thoracic Malignancies in 2021!
We have created tables for indications and their results to stay organized and for a quick reference.
#MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #thyroidcancer
👏This is how the @FDAOncology accelerated approval process is good for patients, in the 15 mos it took to get the official #capmatinib approval I have treated 2 pts w #METEx14 mutations who have had a conplete response. #notinetowait #patientsfirst #lcsm @metcrusaders
#FDA #Capmatinib #GEOMETRYmono1 #ScienceLink
CPCNP metastásico: La FDA aprueba capmatinib
https://t.co/WO60V9ezGj
BREAKING: Regular #FDA approval has been granted to #capmatinib for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test. #nsclc #lcsm
https://t.co/1E9JPGW3s6
#Capmatinib gets regular @US_FDA approval for mNSCLC w/ MET exon 14 skip mutation.
#GEOMETRYmono1: 1L and pre-treated patients
- ORR 67.9% in 1L and 44% in pretreated pts.
- AEs: edema, nausea, and fatigue
#LCSM #MedTwitter #OncTwitter @NovartisCancer #OncEd
⚡️@FDAOncology grants "regular" approval #capmatinib 400 mg BID 💊for metastatic #LCSM with MET ex14 skipping!
⏮️Acc. approval: #GEOMETRY mono-1
Now, with +63 pts/22 mth followup
➡️ORR: 68%, (1L) 44%, (2L)
➡️ mDOR: 16.6 & 9.7 mos
🛑S/E: 🫧🤢😬
👇#Onc1Slider METex14 @OncoAlert
New Ph2 #Amivantamab trial, combination with #Capmatinib -in Unresectable Metastatic Non-small Cell #Lung Cancer -for participants with NSCLC harboring MET exon 14 skipping mutations or MET amplification
$JNJ $GMAB @Genmab $NVS #Novartis #Rybrevant
https://t.co/WI0ErABVNb
Excellent work by the @MayoClinic team. Very important to be aware of AKI and #capmatinib , a well documented lab finding in therapy and how it should be monitored. Read before you dose adjust , hold therapy or change lines of treatment. #LCSM
Creatinine elevation during MET-TKI is not uncommon
A nice case report describing #capmatinib induced pseudo–AKI from @MayoClinic
Using cystatin C and renal iothalamate clearance, they show there was not much variation in GFR despite fluctuating Cr.
https://t.co/hzHbxvg93B
Creatinine elevation during MET-TKI is not uncommon
A nice case report describing #capmatinib induced pseudo–AKI from @MayoClinic
Using cystatin C and renal iothalamate clearance, they show there was not much variation in GFR despite fluctuating Cr.
https://t.co/hzHbxvg93B
🚨@OncoAlert @JTOonline first data on #capmatinib activity in #MET altered, post-crizo #NSCLC
🏑 N=20
🏑 OR:2, SD:14, DCR=80%
🏑Intracran DCR=100% (N=5)
🏑mPFS=5.5m, mOS=11.3m
🏑 D1228, Y1230 resist muts post-crizo, pre-capma
@IASLC @ESMO @ASCO #some @lcsmchat
👏all authors
#Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations #lcsm https://t.co/RKOov6qY3F
🟣🟣🟣🐅#OncVoice
Top 3 oncology news last week:
💊 NIVO + IPI in Sarcomatoid #RCC
#Capmatinib in #NSCLC
#Azacitidine in #AML
Weekly recap with links to news:
https://t.co/aUREtTY353
🟣🟣🟣🐯#LarvolVoice
#Capmatinib - 68% ORR in MET Exon 14–Mutated or MET-Amplified #NSCLC
View reactions from @VivekSubbiah @prat_aleix @oncologician @drdeniztural and other top oncologists
List with links: https://t.co/EWCClYBsvV
Article: https://t.co/FQhT2WzpiY
🚨#OncoAlert Just out in @NEJM #capmatinib efficacy in #MET altered #NSCLC:
➡️ In MET exon14 skipping mut: 41% ORR
➡️In MET amplif and GCN>10: ORR 29% in pretreated pts, 40% in trt naive pts
➡️LOW efficacy in MET amplif and GCN<10: ORR 7-12%
#LCSM @METCrusaders @weoncologists
Last Seen Hashtags on Sotwe
DntLightenUp
Seen from United States
Yourfavbassgyal
Seen from United States
videocall
Seen from France
schoolthot
Seen from United States
ยิ่งลักษณ์ชินวัตร
Seen from Thailand
sarauanglo
Seen from United States
sfbla
Seen from United States
primita
Seen from Mexico
starsessions
Seen from United States
雌堕
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers